Steven J. O’Day

Learn More
Objective: Ipilimumab is a fully human, anti–cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody that has demonstrated antitumor activity in advanced melanoma. We evaluated the safety and efficacy of ipilimumab alone and in combination with dacarbazine (DTIC) in patients with unresectable, metastatic melanoma. Methods: Chemotherapy-naïve patients(More)
BACKGROUND In patients with metastatic melanoma and KIT amplifications and/or mutations, therapy with imatinib mesylate may prolong survival. 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT may be used to assess metabolic response. We investigated associations of metabolic response, mutational status, progression-free survival and overall survival(More)
Purpose: A human monoclonal antibody (L612 HuMAb) that binds to ganglioside GM3 has been developed in our laboratory. L612 HuMAb is a 100% human IgM protein. L612 HuMAb binds to cell surface of melanoma and can kill the cells in the presence of complement. The primary objective of this study was to test the toxicity and pharmacokinetics associated with(More)
Purpose In this Phase 1, multicenter, open-label study, intetumumab (CNTO 95), a fully human anti-αv integrin monoclonal antibody was evaluated for safety, pharmacokinetics, and pharmacodynamic activity in patients with melanoma or angiosarcoma. Patients and methods Patients with histologically-confirmed inoperable melanoma or angiosarcoma refractory to(More)
Jyoti D. Patel, Northwestern University; Blasé Polite, University of Chicago Medicine, Chicago, IL; Lada Krilov, American Society of Clinical Oncology, Alexandria, VA; Sylvia Adams and William L. Carroll, New York University Cancer Institute; Carol Aghajanian, Mark G. Kris, and Gary K. Schwartz, Memorial Sloan-Kettering Cancer Center, New York, NY; Ethan(More)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma Reinhard Dummer, Adil Daud, Igor Puzanov, Omid Hamid, Dirk Schadendorf, Caroline Robert, Jacob Schachter, Anna Pavlick, Rene Gonzalez, F Stephen Hodi, Lee D. Cranmer, Christian Blank, Steven J. O’Day, Paolo A. Ascierto, April K.S. Salama,(More)
BACKGROUND Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude concomitant administration. Concurrent administration of IPI and VEM previously showed significant dose-limiting(More)
Stage IV metastatic melanoma patients historically have a poor prognosis with 5-10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable responses in advanced melanoma. However, less than 25% of those treated benefit, treatment is expensive, and side(More)
The role of estrogen receptor A (ER-A) in melanoma is unknown. ER-A expression may be regulated in melanoma via hypermethylation of promoter CpG islands. We assessed ER-A hypermethylation in primary and metastatic melanomas and sera as a potential tumor progression marker. ER-A methylation status in tumor (n = 107) and sera (n = 109) from American Joint(More)